<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047172</url>
  </required_header>
  <id_info>
    <org_study_id>CED000000522</org_study_id>
    <secondary_id>PRO00033912</secondary_id>
    <secondary_id>1U01NS117450-01A1</secondary_id>
    <nct_id>NCT05047172</nct_id>
  </id_info>
  <brief_title>Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis</brief_title>
  <acronym>CAPTIVA</acronym>
  <official_title>Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of the trial is to determine if the experimental arms (rivaroxaban or&#xD;
      ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of&#xD;
      ischemic stroke, intracerebral hemorrhage, or vascular death.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is relevant to public health because narrowing of brain arteries is one of&#xD;
      the most common causes of stroke worldwide. Compelling evidence suggests novel antithrombotic&#xD;
      medications could reduce the rate of stroke in patients with narrowed brain arteries. The&#xD;
      proposed study will directly compare novel antithrombotic medications to standard care&#xD;
      antiplatelet medications for preventing stroke and death from vascular causes in patients&#xD;
      with narrowed brain arteries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 3, 2022</start_date>
  <completion_date type="Anticipated">January 3, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 3, 2027</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>1:1:1 treatment allocation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with intracerebral hemorrhage (ICH) or non-intracranial hemorrhage (ICH) major bleeding</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Major non-ICH hemorrhage is defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria consisting of:&#xD;
Fatal bleeding&#xD;
Symptomatic bleeding in a critical area or organ, such as intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or&#xD;
Symptomatic bleeding causing a fall in hemoglobin level of 20g L-1 (1.24 mmol L-1) or more or leading to transfusion of two or more units of whole blood or red cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with ischemic stroke, intracerebral hemorrhage or vascular death</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The definition of ischemic stroke is the American Heart Association definition that also includes signs or symptoms lasting &lt; 24 hours associated with an acute infarct on brain imaging.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1683</enrollment>
  <condition>Intracranial Arteriosclerosis</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Experimental Arm: Ticagrelor and Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor (180mg loading dose, then 90mg twice daily) and aspirin (81mg daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Arm: Clopidogrel and Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel (600mg loading dose, then 75mg once daily) and aspirin (81mg daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Arm: Rivaroxaban and Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban (2.5mg twice daily) and aspirin (81mg daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor + Aspirin</intervention_name>
    <description>ticagrelor (180 mg loading dose, then 90mg twice daily) and aspirin (81mg daily)</description>
    <arm_group_label>Experimental Arm: Ticagrelor and Aspirin</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban + Aspirin</intervention_name>
    <description>low dose rivaroxaban (2.5mg twice daily) and aspirin (81mg daily)</description>
    <arm_group_label>Experimental Arm: Rivaroxaban and Aspirin</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel + Aspirin</intervention_name>
    <description>clopidogrel (600mg loading dose, then 75mg daily) and aspirin (81mg daily)</description>
    <arm_group_label>Standard of Care Arm: Clopidogrel and Aspirin</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Risk Factor Management</intervention_name>
    <description>Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed.</description>
    <arm_group_label>Experimental Arm: Rivaroxaban and Aspirin</arm_group_label>
    <arm_group_label>Experimental Arm: Ticagrelor and Aspirin</arm_group_label>
    <arm_group_label>Standard of Care Arm: Clopidogrel and Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptoms or signs of any duration associated with an infarct on brain imaging that&#xD;
             occurred within 30 days prior to randomization&#xD;
&#xD;
          -  Index infarct is attributed to 70-99% stenosis (or flow gap on MRA) of a major&#xD;
             intracranial artery (carotid artery, MCA stem (M1), vertebral artery, or basilar&#xD;
             artery) documented by CTA, MRA, or catheter angiography&#xD;
&#xD;
          -  Modified Rankin score of â‰¤ 4&#xD;
&#xD;
          -  Ability to swallow pills&#xD;
&#xD;
          -  Age 30-80 years, inclusive, at time of consent&#xD;
&#xD;
          -  Subjects 30-49 years of age are required to meet at least one of the following&#xD;
             additional criteria below to qualify for the study:&#xD;
&#xD;
          -  diabetes treated with insulin for at least 15 years&#xD;
&#xD;
          -  at least 2 of the following atherosclerotic risk factors: hypertension (BP &gt; 140/90 or&#xD;
             on antihypertensive therapy); dyslipidemia (LDL &gt; 130 mg /dl or HDL &lt; 40 mg/dl or&#xD;
             fasting triglycerides &gt; 150 mg/dl or on lipid lowering therapy); smoking; non-insulin&#xD;
             dependent diabetes or insulin dependent diabetes of less than 15 years duration; any&#xD;
             of the following vascular events occurring in a parent or sibling who was &lt; 55 years&#xD;
             of age for men or &lt; 65 years of age for women at the time of the event: myocardial&#xD;
             infarction, coronary artery bypass, coronary angioplasty or stenting, stroke, carotid&#xD;
             endarterectomy or stenting, peripheral vascular surgery for atherosclerotic disease&#xD;
&#xD;
          -  personal history of any of the following: myocardial infarction, coronary artery&#xD;
             bypass, coronary angioplasty or stenting, carotid endarterectomy or stenting, or&#xD;
             peripheral vascular surgery for atherosclerotic disease&#xD;
&#xD;
          -  any stenosis of an extracranial carotid or vertebral artery, another intracranial&#xD;
             artery, subclavian artery, coronary artery, iliac or femoral artery, other lower or&#xD;
             upper extremity artery, mesenteric artery, or renal artery that was documented by&#xD;
             non-invasive vascular imaging or catheter angiography and is considered&#xD;
             atherosclerotic&#xD;
&#xD;
          -  aortic arch atheroma documented by non-invasive vascular imaging or catheter&#xD;
             angiography&#xD;
&#xD;
          -  any aortic aneurysm documented by non-invasive vascular imaging or catheter&#xD;
             angiography that is considered atherosclerotic&#xD;
&#xD;
          -  Negative pregnancy test in a female who has had any menses in the last 18 months and&#xD;
             has not had surgery that would make her unable to become pregnant&#xD;
&#xD;
          -  Subject is willing and able to return for all follow-up visits required by the&#xD;
             protocol&#xD;
&#xD;
          -  Subject is available by phone&#xD;
&#xD;
          -  Subject understands the purpose and requirements of the study and can make him/herself&#xD;
             understood&#xD;
&#xD;
          -  Subject has provided informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment of target lesion with a stent, angioplasty, or other mechanical&#xD;
             device, or plan to perform one of these procedures&#xD;
&#xD;
          -  Plan to perform concomitant angioplasty or stenting of an extracranial vessel tandem&#xD;
             to the symptomatic intracranial stenosis&#xD;
&#xD;
          -  Intracranial tumor (except meningioma) or any intracranial vascular malformation&#xD;
&#xD;
          -  Thrombolytic therapy within 24 hours prior to randomization&#xD;
&#xD;
          -  Progressive neurological signs within 24 hours prior to randomization&#xD;
&#xD;
          -  History of any intracranial hemorrhage (parenchymal, subarachnoid, subdural, epidural)&#xD;
&#xD;
          -  Intracranial arterial stenosis due to arterial dissection; MoyaMoya disease; any known&#xD;
             vasculitic disease; herpes zoster, varicella zoster or other viral vasculopathy;&#xD;
             neurosyphilis; any other intracranial infection; any intracranial stenosis associated&#xD;
             with CSF pleocytosis; radiation induced vasculopathy; fibromuscular dysplasia; sickle&#xD;
             cell disease; neurofibromatosis; benign angiopathy of central nervous system;&#xD;
             postpartum angiopathy; suspected vasospastic process; reversible cerebral&#xD;
             vasoconstriction syndrome (RCVS); suspected recanalized embolus&#xD;
&#xD;
          -  Presence of any of the following unequivocal cardiac sources of embolism: chronic or&#xD;
             paroxysmal atrial fibrillation, mitral stenosis, mechanical valve, endocarditis,&#xD;
             intracardiac clot or vegetation, myocardial infarction within three months, left&#xD;
             atrial spontaneous echo contrast&#xD;
&#xD;
          -  Known allergy or contraindication to aspirin, rivaroxaban, clopidogrel, or ticagrelor.&#xD;
&#xD;
          -  Active peptic ulcer disease, major systemic hemorrhage within 30 days prior to&#xD;
             randomization, active bleed or bleeding diathesis, platelets &lt; 100,000, hematocrit &lt;&#xD;
             30, INR &gt; 1.5, clotting factor abnormality that increases the risk of bleeding,&#xD;
             current alcohol or substance abuse, uncontrolled severe hypertension (systolic&#xD;
             pressure &gt; 180 mm Hg or diastolic pressure &gt; 115 mm Hg), severe liver impairment (AST&#xD;
             or ALT &gt; 3 x normal, cirrhosis), on dialysis&#xD;
&#xD;
          -  Major surgery (including open femoral, aortic, or carotid surgery, cardiac) within&#xD;
             previous 30 days prior to randomization or planned in the next 90 days after&#xD;
             randomization&#xD;
&#xD;
          -  Any condition other than intracranial arterial stenosis that requires the subject to&#xD;
             take any antithrombotic medication other than aspirin (NOTE: exceptions allowed for&#xD;
             subcutaneous heparin for deep vein thrombosis (DVT) prophylaxis while hospitalized)&#xD;
&#xD;
          -  Severe neurological deficit that renders the subject incapable of living independently&#xD;
&#xD;
          -  Dementia or psychiatric problem that prevents the subject from following an outpatient&#xD;
             program reliably&#xD;
&#xD;
          -  Co-morbid conditions that may limit survival to less than 12 months&#xD;
&#xD;
          -  Pregnancy or of childbearing potential and unwilling to use contraception for the&#xD;
             duration of this study, or currently breastfeeding&#xD;
&#xD;
          -  Current or anticipated concomitant oral or intravenous therapy with strong CYP3A4&#xD;
             inhibitors or CYP3A4 substrates that cannot be stopped for the course of this study&#xD;
&#xD;
          -  Enrollment in another study that would conflict with the current study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian L. Hoh, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc I. Chimowitz, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Smith, MSN, RN</last_name>
    <phone>352-273-7773</phone>
    <email>jessica.smith@neurosurgery.ufl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Renee Boyette, BSN, RN</last_name>
    <phone>352-273-7935</phone>
    <email>renee.boyette@neurosurgery.ufl.edu</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Arteriosclerosis</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

